疫苗制造商Novavax (NVAX)股价经历了一年的过山车式波动。5月，该公司宣布与生物科技巨头赛诺菲达成一项利润丰厚的协议后，股价飙升。自那以后，Novavax的股价一直在走下坡路，不过这可能是由于一些投资者获利回吐。

As of 21 October at 3:10 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...